Compare Crispr Therapeutics AG (CRSP) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ferrari NV — how do they compare? Crispr Therapeutics AG trades at $50.36 (market cap $4.97B), while Ferrari NV trades at $376.5 (market cap $65.00B). The key difference: Ferrari NV is far larger — about 13.1× Crispr Therapeutics AG's market cap, and Ferrari NV pays a 1.14% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | RACE | |
|---|---|---|
Market Cap | $4.97B | $65.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $517.65 |
52-Week Low | $44.34 | $314.63 |
Enterprise Value | $3.32B | $66.21B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Ferrari (RACE) trades at $372.98, down 0.97% on the day, with a bullish technical signal supported by moving averages. The stock exhibits strong profitability with a net income margin of 22.19% and robust revenue growth from $5.1B in 2022 to $7.1B in 2025. Recent news highlights the company's ongoing share buyback program and strategic moves in the EV space, though the Luce model has faced some market skepticism.
The outlook remains positive with a consensus price target of $467.50, implying significant upside. Key opportunities include pricing power and margin strength, while risks involve execution on EV strategy and high valuation multiples. Earnings consistently beat expectations, supporting the bullish analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
